CRISPR 기반 진단 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 제품별, 기술별, 용도별, 최종사용자별, 지역별 부문, 경쟁(2020-2030년)
CRISPR-Based Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Technology, By Application, By End User, By Region and Competition, 2020-2030F
세계의 CRISPR 기반 진단 시장은 2024년에 31억 6,000만 달러로 평가되며, 예측 기간 중 CAGR 17.02%로 성장하며, 2030년에는 81억 2,000만 달러에 달할 것으로 예측됩니다.
이 시장은 정확하고 비용 효율적이며 신속한 분자진단 툴에 대한 수요가 증가함에 따라 빠르게 성장하고 있으며, CRISPR 기반 진단은 유전자 편집 메커니즘을 이용하여 DNA 또는 RNA 서열을 정밀하게 검출하여 감염성 질환, 유전성 질환 및 암을 조기에 발견할 수 있도록 지원합니다. 현장 검사, 맞춤형 의료, 동반 진단에 이러한 툴의 적용이 증가함에 따라 시장 채택이 가속화되고 있습니다. 연구 투자 확대, 생명공학 기업과 학계의 공동 연구, 분산형 검사로의 전환은 성장을 더욱 촉진하고 있습니다. 이러한 진단 툴은 시료 전처리를 최소화하고 고급 실험실 인프라 없이도 결과를 제공하므로 임상 환경과 원격 환경에 모두 적합합니다.
| 시장 개요 |
| 예측 기간 |
2026-2030 |
| 시장 규모 : 2024년 |
31억 6,000만 달러 |
| 시장 규모 : 2030년 |
81억 2,000만 달러 |
| CAGR : 2025-2030년 |
17.02% |
| 급성장 부문 |
암 진단약 |
| 최대 시장 |
북미 |
시장 성장 촉진요인
CRISPR 기술 및 플랫폼 개발 현황
주요 시장 이슈
제한된 임상 검증 및 표준화
주요 시장 동향
POC(Point-Of-Care) 및 재택 검사 용도 확대
목차
제1장 개요
제2장 조사 방법
제3장 개요
제4장 고객의 소리
제5장 세계의 CRISPR 기반 진단 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 제품별(효소, 키트 및 시약, 소프트웨어 및 라이브러리)
- 기술별(Cas9, Cas12, 기타)
- 용도별(감염증 진단, 유전성 질환 진단, 암 진단, 기타)
- 최종사용자별(병원·진료소, 진단, 연구소, 제약·바이오테크놀러지 기업, 기타)
- 기업별(2024)
- 지역별
- 시장 맵
제6장 북미의 CRISPR 기반 진단 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 북미 : 국가별 분석
제7장 유럽의 CRISPR 기반 진단 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 유럽 : 국가별 분석
제8장 아시아태평양의 CRISPR 기반 진단 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 아시아태평양 : 국가별 분석
제9장 남미의 CRISPR 기반 진단 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 CRISPR 기반 진단 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 중동 및 아프리카 : 국가별 분석
제11장 시장 역학
제12장 시장 동향과 발전
제13장 혼란 : 분쟁, 팬데믹, 무역장벽
제14장 Porter's Five Forces 분석
- 업계내 경쟁
- 신규 참여의 가능성
- 공급업체의 힘
- 고객의 힘
- 대체품의 위협
제15장 경쟁 구도
- Thermo Fisher Scientific Inc.
- Integrated DNA Technologies, Inc.
- Molbio Diagnostics
- Horizon Discovery
- Synthego Corporation
- Mammoth Biosciences
- Sherlock Biosciences
- Caribou Biosciences
- CrisprBits
- ToolGen Inc.
제16장 전략적 제안
제17장 조사회사 소개·면책사항
KSA
The Global CRISPR-Based Diagnostics Market was valued at USD 3.16 billion in 2024 and is projected to reach USD 8.12 billion by 2030, growing at a CAGR of 17.02% during the forecast period. This market is witnessing rapid growth due to rising demand for accurate, cost-efficient, and fast molecular diagnostic tools. CRISPR-based diagnostics utilize gene-editing mechanisms to detect DNA or RNA sequences with high precision, aiding early identification of infectious diseases, genetic conditions, and cancers. The increasing application of these tools in point-of-care testing, personalized medicine, and companion diagnostics is accelerating market adoption. Growth is further fueled by expanding research investments, collaborations between biotech firms and academic institutions, and a shift toward decentralized testing. These diagnostics offer results with minimal sample preparation and without the need for advanced lab infrastructure, making them well-suited for both clinical and remote environments.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 3.16 Billion |
| Market Size 2030 | USD 8.12 Billion |
| CAGR 2025-2030 | 17.02% |
| Fastest Growing Segment | Cancer Diagnostics |
| Largest Market | North America |
Key Market Drivers
Advancements in CRISPR Technology and Platform Development
Technological progress in CRISPR systems and platform innovations is significantly contributing to market growth. Enhanced enzyme engineering has improved the specificity and efficiency of Cas variants like Cas12, Cas13, and Cas14, enabling detection of multiple biomarkers with reduced off-target effects. Developments in portable diagnostic formats-such as lateral-flow strips, paper-based assays, and microfluidic devices-have made CRISPR tools accessible and easy to use, even outside of laboratory settings. Integration with AI for guide RNA design and interpretation software has improved diagnostic accuracy and user experience. Public-sector initiatives are also fostering innovation; for example, the NIH's Somatic Cell Genome Editing (SCGE) Program allocated USD 89 million in 2024 to improve genome-editing technologies, while a USD 27 million project launched a Genomics Learning Health System Network to incorporate genomic diagnostics into routine care.
Key Market Challenges
Limited Clinical Validation and Standardization
Despite promising laboratory results, CRISPR-based diagnostics face hurdles due to limited clinical validation and lack of standardization. Large-scale, peer-reviewed clinical trials evaluating these technologies across diverse populations and biological sample types are still sparse. Many current assays lack proven efficacy in complex samples such as blood or saliva, where potential interferences can compromise accuracy. This insufficient validation presents challenges for regulatory approvals and delays adoption in clinical settings. Medical institutions require comprehensive, reproducible evidence to trust and implement new diagnostic platforms, and the current data gaps hinder wider integration into healthcare systems.
Key Market Trends
Expansion of Point-of-Care and At-Home Testing Applications
The move toward decentralized diagnostic solutions is shaping the growth trajectory of CRISPR-based diagnostics. Traditional lab-based diagnostics can be slow and require skilled personnel, but CRISPR platforms offer a quicker, simpler alternative. Innovations in lyophilized reagents, compact lateral flow systems, and microfluidic devices have paved the way for CRISPR-based tests suitable for primary care, pharmacies, and even home use. These solutions are particularly valuable in low-resource or rural settings. Growing interest in remote healthcare and instant diagnostic results-especially for infectious diseases, chronic conditions, and genetic screening-is fueling demand. Additionally, smartphone-compatible, user-operated devices are gaining popularity among consumers. Features such as disposable cartridges, refrigeration-free storage, and minimal training requirements are making CRISPR diagnostics increasingly viable for widespread, non-laboratory applications.
Key Market Players
- Thermo Fisher Scientific Inc.
- Integrated DNA Technologies, Inc.
- Molbio Diagnostics
- Horizon Discovery
- Synthego Corporation
- Mammoth Biosciences
- Sherlock Biosciences
- Caribou Biosciences
- CrisprBits
- ToolGen Inc.
Report Scope:
In this report, the Global CRISPR-Based Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
CRISPR-Based Diagnostics Market, By Product:
- Enzymes
- Kits and Reagents
- Software and Libraries
CRISPR-Based Diagnostics Market, By Technology:
CRISPR-Based Diagnostics Market, By Application:
- Infectious Disease Diagnostics
- Genetic Disorder Diagnostics
- Cancer Diagnostics
- Others
CRISPR-Based Diagnostics Market, By End User:
- Hospitals and Clinics Diagnostic
- Laboratories
- Pharmaceutical and Biotechnology Companies
- Others
CRISPR-Based Diagnostics Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global CRISPR-Based Diagnostics Market.
Available Customizations:
Global CRISPR-Based Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, and Trends
4. Voice of Customer
5. Global CRISPR-Based Diagnostics Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Product (Enzymes, Kits and Reagents, Software and Libraries)
- 5.2.2. By Technology (Cas9, Cas12, Others)
- 5.2.3. By Application (Infectious Disease Diagnostics, Genetic Disorder Diagnostics, Cancer Diagnostics, Others)
- 5.2.4. By End User (Hospitals and Clinics Diagnostic, Laboratories, Pharmaceutical and Biotechnology Companies, Others)
- 5.2.5. By Company (2024)
- 5.2.6. By Region
- 5.3. Market Map
6. North America CRISPR-Based Diagnostics Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Technology
- 6.2.3. By Application
- 6.2.4. By End User
- 6.2.5. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States CRISPR-Based Diagnostics Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Product
- 6.3.1.2.2. By Technology
- 6.3.1.2.3. By Application
- 6.3.1.2.4. By End User
- 6.3.2. Mexico CRISPR-Based Diagnostics Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Product
- 6.3.2.2.2. By Technology
- 6.3.2.2.3. By Application
- 6.3.2.2.4. By End User
- 6.3.3. Canada CRISPR-Based Diagnostics Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Product
- 6.3.3.2.2. By Technology
- 6.3.3.2.3. By Application
- 6.3.3.2.4. By End User
7. Europe CRISPR-Based Diagnostics Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Technology
- 7.2.3. By Application
- 7.2.4. By End User
- 7.2.5. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. France CRISPR-Based Diagnostics Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Product
- 7.3.1.2.2. By Technology
- 7.3.1.2.3. By Application
- 7.3.1.2.4. By End User
- 7.3.2. Germany CRISPR-Based Diagnostics Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Product
- 7.3.2.2.2. By Technology
- 7.3.2.2.3. By Application
- 7.3.2.2.4. By End User
- 7.3.3. United Kingdom CRISPR-Based Diagnostics Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Product
- 7.3.3.2.2. By Technology
- 7.3.3.2.3. By Application
- 7.3.3.2.4. By End User
- 7.3.4. Italy CRISPR-Based Diagnostics Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Product
- 7.3.4.2.2. By Technology
- 7.3.4.2.3. By Application
- 7.3.4.2.4. By End User
- 7.3.5. Spain CRISPR-Based Diagnostics Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Product
- 7.3.5.2.2. By Technology
- 7.3.5.2.3. By Application
- 7.3.5.2.4. By End User
8. Asia-Pacific CRISPR-Based Diagnostics Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Technology
- 8.2.3. By Application
- 8.2.4. By End User
- 8.2.5. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China CRISPR-Based Diagnostics Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Product
- 8.3.1.2.2. By Technology
- 8.3.1.2.3. By Application
- 8.3.1.2.4. By End User
- 8.3.2. India CRISPR-Based Diagnostics Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Product
- 8.3.2.2.2. By Technology
- 8.3.2.2.3. By Application
- 8.3.2.2.4. By End User
- 8.3.3. South Korea CRISPR-Based Diagnostics Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Product
- 8.3.3.2.2. By Technology
- 8.3.3.2.3. By Application
- 8.3.3.2.4. By End User
- 8.3.4. Japan CRISPR-Based Diagnostics Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Product
- 8.3.4.2.2. By Technology
- 8.3.4.2.3. By Application
- 8.3.4.2.4. By End User
- 8.3.5. Australia CRISPR-Based Diagnostics Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Product
- 8.3.5.2.2. By Technology
- 8.3.5.2.3. By Application
- 8.3.5.2.4. By End User
9. South America CRISPR-Based Diagnostics Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Technology
- 9.2.3. By Application
- 9.2.4. By End User
- 9.2.5. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil CRISPR-Based Diagnostics Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Product
- 9.3.1.2.2. By Technology
- 9.3.1.2.3. By Application
- 9.3.1.2.4. By End User
- 9.3.2. Argentina CRISPR-Based Diagnostics Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Product
- 9.3.2.2.2. By Technology
- 9.3.2.2.3. By Application
- 9.3.2.2.4. By End User
- 9.3.3. Colombia CRISPR-Based Diagnostics Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Product
- 9.3.3.2.2. By Technology
- 9.3.3.2.3. By Application
- 9.3.3.2.4. By End User
10. Middle East and Africa CRISPR-Based Diagnostics Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Technology
- 10.2.3. By Application
- 10.2.4. By End User
- 10.2.5. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa CRISPR-Based Diagnostics Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Product
- 10.3.1.2.2. By Technology
- 10.3.1.2.3. By Application
- 10.3.1.2.4. By End User
- 10.3.2. Saudi Arabia CRISPR-Based Diagnostics Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Product
- 10.3.2.2.2. By Technology
- 10.3.2.2.3. By Application
- 10.3.2.2.4. By End User
- 10.3.3. UAE CRISPR-Based Diagnostics Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Product
- 10.3.3.2.2. By Technology
- 10.3.3.2.3. By Application
- 10.3.3.2.4. By End User
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Merger & Acquisition (If Any)
- 12.2. Product Launches (If Any)
- 12.3. Recent Developments
13. Disruptions: Conflicts, Pandemics and Trade Barriers
14. Porters Five Forces Analysis
- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Products
15. Competitive Landscape
- 15.1. Thermo Fisher Scientific Inc.
- 15.1.1. Business Overview
- 15.1.2. Company Snapshot
- 15.1.3. Products & Services
- 15.1.4. Financials (As Reported)
- 15.1.5. Recent Developments
- 15.1.6. Key Personnel Details
- 15.1.7. SWOT Analysis
- 15.2. Integrated DNA Technologies, Inc.
- 15.3. Molbio Diagnostics
- 15.4. Horizon Discovery
- 15.5. Synthego Corporation
- 15.6. Mammoth Biosciences
- 15.7. Sherlock Biosciences
- 15.8. Caribou Biosciences
- 15.9. CrisprBits
- 15.10. ToolGen Inc.
16. Strategic Recommendations
17. About Us & Disclaimer
